Cargando…

Prediction of survival in amyotrophic lateral sclerosis: a nationwide, Danish cohort study

INTRODUCTION: Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease with great heterogeneity. Biological prognostic markers are needed for the patients to plan future supportive treatment, palliative treatment, and end-of-life decisions. In addition, prognostic markers are greatl...

Descripción completa

Detalles Bibliográficos
Autores principales: Kjældgaard, Anne-Lene, Pilely, Katrine, Olsen, Karsten Skovgaard, Jessen, Anders Hedegaard, Lauritsen, Anne Øberg, Pedersen, Stephen Wørlich, Svenstrup, Kirsten, Karlsborg, Merete, Thagesen, Helle, Blaabjerg, Morten, Theódórsdóttir, Ásta, Elmo, Elisabeth Gundtoft, Møller, Anette Torvin, Bonefeld, Lone, Berg, Mia, Garred, Peter, Møller, Kirsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052712/
https://www.ncbi.nlm.nih.gov/pubmed/33865343
http://dx.doi.org/10.1186/s12883-021-02187-8
_version_ 1783679977811607552
author Kjældgaard, Anne-Lene
Pilely, Katrine
Olsen, Karsten Skovgaard
Jessen, Anders Hedegaard
Lauritsen, Anne Øberg
Pedersen, Stephen Wørlich
Svenstrup, Kirsten
Karlsborg, Merete
Thagesen, Helle
Blaabjerg, Morten
Theódórsdóttir, Ásta
Elmo, Elisabeth Gundtoft
Møller, Anette Torvin
Bonefeld, Lone
Berg, Mia
Garred, Peter
Møller, Kirsten
author_facet Kjældgaard, Anne-Lene
Pilely, Katrine
Olsen, Karsten Skovgaard
Jessen, Anders Hedegaard
Lauritsen, Anne Øberg
Pedersen, Stephen Wørlich
Svenstrup, Kirsten
Karlsborg, Merete
Thagesen, Helle
Blaabjerg, Morten
Theódórsdóttir, Ásta
Elmo, Elisabeth Gundtoft
Møller, Anette Torvin
Bonefeld, Lone
Berg, Mia
Garred, Peter
Møller, Kirsten
author_sort Kjældgaard, Anne-Lene
collection PubMed
description INTRODUCTION: Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease with great heterogeneity. Biological prognostic markers are needed for the patients to plan future supportive treatment, palliative treatment, and end-of-life decisions. In addition, prognostic markers are greatly needed for the randomization in clinical trials. OBJECTIVE: This study aimed to test the ALS Functional Rating Scale-Revised (ALSFRS-R) progression rate (ΔFS) as a prognostic marker of survival in a Danish ALS cohort. METHODS: The ALSFRS-R score at test date in association with duration of symptoms, from the onset of symptoms until test date, (defined as ΔFS’) was calculated for 90 Danish patients diagnosed with either probable or definite sporadic ALS. Median survival time was then estimated from the onset of symptoms until primary endpoint (either death or tracheostomy). ΔFS’ was subjected to survival analysis using Cox proportional hazards modelling, log-rank test, and Kaplan-Meier survival analysis. RESULTS AND CONCLUSIONS: Both ΔFS’ and age was found to be strong predictors of survival of the Danish ALS cohort. Both variables are easily obtained at the time of diagnosis and could be used by clinicians and ALS patients to plan future supportive and palliative treatment. Furthermore, ΔFS’, is a simple, prognostic marker that predicts survival in the early phase of disease as well as at later stages of the disease.
format Online
Article
Text
id pubmed-8052712
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80527122021-04-19 Prediction of survival in amyotrophic lateral sclerosis: a nationwide, Danish cohort study Kjældgaard, Anne-Lene Pilely, Katrine Olsen, Karsten Skovgaard Jessen, Anders Hedegaard Lauritsen, Anne Øberg Pedersen, Stephen Wørlich Svenstrup, Kirsten Karlsborg, Merete Thagesen, Helle Blaabjerg, Morten Theódórsdóttir, Ásta Elmo, Elisabeth Gundtoft Møller, Anette Torvin Bonefeld, Lone Berg, Mia Garred, Peter Møller, Kirsten BMC Neurol Research Article INTRODUCTION: Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease with great heterogeneity. Biological prognostic markers are needed for the patients to plan future supportive treatment, palliative treatment, and end-of-life decisions. In addition, prognostic markers are greatly needed for the randomization in clinical trials. OBJECTIVE: This study aimed to test the ALS Functional Rating Scale-Revised (ALSFRS-R) progression rate (ΔFS) as a prognostic marker of survival in a Danish ALS cohort. METHODS: The ALSFRS-R score at test date in association with duration of symptoms, from the onset of symptoms until test date, (defined as ΔFS’) was calculated for 90 Danish patients diagnosed with either probable or definite sporadic ALS. Median survival time was then estimated from the onset of symptoms until primary endpoint (either death or tracheostomy). ΔFS’ was subjected to survival analysis using Cox proportional hazards modelling, log-rank test, and Kaplan-Meier survival analysis. RESULTS AND CONCLUSIONS: Both ΔFS’ and age was found to be strong predictors of survival of the Danish ALS cohort. Both variables are easily obtained at the time of diagnosis and could be used by clinicians and ALS patients to plan future supportive and palliative treatment. Furthermore, ΔFS’, is a simple, prognostic marker that predicts survival in the early phase of disease as well as at later stages of the disease. BioMed Central 2021-04-17 /pmc/articles/PMC8052712/ /pubmed/33865343 http://dx.doi.org/10.1186/s12883-021-02187-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Kjældgaard, Anne-Lene
Pilely, Katrine
Olsen, Karsten Skovgaard
Jessen, Anders Hedegaard
Lauritsen, Anne Øberg
Pedersen, Stephen Wørlich
Svenstrup, Kirsten
Karlsborg, Merete
Thagesen, Helle
Blaabjerg, Morten
Theódórsdóttir, Ásta
Elmo, Elisabeth Gundtoft
Møller, Anette Torvin
Bonefeld, Lone
Berg, Mia
Garred, Peter
Møller, Kirsten
Prediction of survival in amyotrophic lateral sclerosis: a nationwide, Danish cohort study
title Prediction of survival in amyotrophic lateral sclerosis: a nationwide, Danish cohort study
title_full Prediction of survival in amyotrophic lateral sclerosis: a nationwide, Danish cohort study
title_fullStr Prediction of survival in amyotrophic lateral sclerosis: a nationwide, Danish cohort study
title_full_unstemmed Prediction of survival in amyotrophic lateral sclerosis: a nationwide, Danish cohort study
title_short Prediction of survival in amyotrophic lateral sclerosis: a nationwide, Danish cohort study
title_sort prediction of survival in amyotrophic lateral sclerosis: a nationwide, danish cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052712/
https://www.ncbi.nlm.nih.gov/pubmed/33865343
http://dx.doi.org/10.1186/s12883-021-02187-8
work_keys_str_mv AT kjældgaardannelene predictionofsurvivalinamyotrophiclateralsclerosisanationwidedanishcohortstudy
AT pilelykatrine predictionofsurvivalinamyotrophiclateralsclerosisanationwidedanishcohortstudy
AT olsenkarstenskovgaard predictionofsurvivalinamyotrophiclateralsclerosisanationwidedanishcohortstudy
AT jessenandershedegaard predictionofsurvivalinamyotrophiclateralsclerosisanationwidedanishcohortstudy
AT lauritsenanneøberg predictionofsurvivalinamyotrophiclateralsclerosisanationwidedanishcohortstudy
AT pedersenstephenwørlich predictionofsurvivalinamyotrophiclateralsclerosisanationwidedanishcohortstudy
AT svenstrupkirsten predictionofsurvivalinamyotrophiclateralsclerosisanationwidedanishcohortstudy
AT karlsborgmerete predictionofsurvivalinamyotrophiclateralsclerosisanationwidedanishcohortstudy
AT thagesenhelle predictionofsurvivalinamyotrophiclateralsclerosisanationwidedanishcohortstudy
AT blaabjergmorten predictionofsurvivalinamyotrophiclateralsclerosisanationwidedanishcohortstudy
AT theodorsdottirasta predictionofsurvivalinamyotrophiclateralsclerosisanationwidedanishcohortstudy
AT elmoelisabethgundtoft predictionofsurvivalinamyotrophiclateralsclerosisanationwidedanishcohortstudy
AT mølleranettetorvin predictionofsurvivalinamyotrophiclateralsclerosisanationwidedanishcohortstudy
AT bonefeldlone predictionofsurvivalinamyotrophiclateralsclerosisanationwidedanishcohortstudy
AT bergmia predictionofsurvivalinamyotrophiclateralsclerosisanationwidedanishcohortstudy
AT garredpeter predictionofsurvivalinamyotrophiclateralsclerosisanationwidedanishcohortstudy
AT møllerkirsten predictionofsurvivalinamyotrophiclateralsclerosisanationwidedanishcohortstudy